Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KYTX Stock Forecast 2026-2027
$9.93
Current Price
$601.07M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to KYTX Price Targets
+232.3%
To High Target of $33.00
+222.3%
To Median Target of $32.00
+101.4%
To Low Target of $20.00
KYTX Price Momentum
+10.9%
1 Week Change
+16.3%
1 Month Change
+433.9%
1 Year Change
+5.6%
Year-to-Date Change
-27.4%
From 52W High of $13.67
+457.9%
From 52W Low of $1.78
📊 TOP ANALYST CALLS
Did KYTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Kyverna is one of their latest high-conviction picks.
Latest KYTX Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, KYTX has a bullish consensus with a median price target of $32.00 (ranging from $20.00 to $33.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $9.93, the median forecast implies a 222.3% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Derek Archila at Wells Fargo, projecting a 232.3% upside. Conversely, the most conservative target is provided by Mitchell S. Kapoor at HC Wainwright & Co., suggesting a 101.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KYTX Analyst Ratings
6
Buy
0
Hold
0
Sell
KYTX Price Target Range
Low
$20.00
Average
$32.00
High
$33.00
Current: $9.93
Latest KYTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KYTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 16, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $33.00 |
| Dec 4, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $25.00 |
| Oct 30, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $31.00 |
| Oct 27, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $20.00 |
| Oct 8, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $27.00 |
| Aug 29, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $10.00 |
| Aug 20, 2025 | William Blair | Sami Corwin | Outperform | Initiates | $N/A |
| May 27, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Upgrade | $5.00 |
| Apr 3, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Maintains | $4.00 |
| Apr 1, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $20.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Maintains | $6.00 |
| Nov 15, 2024 | Wells Fargo | Derek Archila | Overweight | Maintains | $24.00 |
| Oct 10, 2024 | UBS | Trung Huynh | Buy | Initiates | $13.00 |
| Sep 19, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $7.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Maintains | $7.00 |
| Jul 31, 2024 | JP Morgan | Brian Cheng | Overweight | Maintains | $33.00 |
| Jul 16, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $8.00 |
| Jul 3, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Initiates | $8.00 |
| Mar 4, 2024 | JP Morgan | Brian Cheng | Overweight | Initiates | $39.00 |
| Mar 4, 2024 | Morgan Stanley | Michael Ulz | Overweight | Initiates | $40.00 |
Kyverna Therapeutics, Inc. (KYTX) Competitors
The following stocks are similar to Kyverna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kyverna Therapeutics, Inc. (KYTX) Financial Data
Kyverna Therapeutics, Inc. has a market capitalization of $601.07M with a P/E ratio of -2.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -64.7%.
Valuation Metrics
Market Cap
$601.07M
Enterprise Value
$325.92M
P/E Ratio
-2.7x
PEG Ratio
-3.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+46.5%
Current Ratio
7.8x
Debt/Equity
12.5x
ROE
-64.7%
ROA
-35.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Kyverna Therapeutics, Inc. (KYTX) Business Model
About Kyverna Therapeutics, Inc.
What They Do
Develops innovative therapeutics for autoimmune diseases.
Business Model
Kyverna Therapeutics generates revenue through the development and commercialization of advanced cell therapies, specifically engineered T cell therapies aimed at treating autoimmune disorders. The company focuses on R&D to create solutions that can provide long-lasting relief and improve patients' quality of life.
Additional Information
Headquartered in the United States, Kyverna Therapeutics is positioned in a rapidly growing market, aiming to transform treatment paradigms for chronic autoimmune conditions. The company's unique approach to resetting the immune system's balance represents a significant advancement in less invasive therapeutic options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
130
CEO
Mr. Warner Biddle
Country
United States
IPO Year
N/A
Website
kyvernatx.comKyverna Therapeutics, Inc. (KYTX) Latest News & Analysis
Latest News
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
10 days ago
Quick Summary
Kyverna Therapeutics (Nasdaq: KYTX) will hold a conference call on April 22, 2026, at 7:00 a.m. to discuss its developments in cell therapies for autoimmune diseases.
Why It Matters
Kyverna's upcoming conference call may provide key updates on its cell therapies and clinical progress, potentially influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A company is preparing to launch its first-to-market CAR T therapy for stiff person syndrome, with a Biologics License Application (BLA) submission expected in the first half of 2026.
Why It Matters
The upcoming BLA submission for a CAR T therapy targeting stiff person syndrome indicates potential market leadership and revenue growth, impacting the company's valuation and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
1 month ago
Quick Summary
Kyverna Therapeutics, Inc. (KYTX) presented at the Leerink Global Healthcare Conference 2026, sharing insights and updates relevant to investors.
Why It Matters
Kyverna's presentation at a major healthcare conference signals potential advancements in its pipeline, impacting investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Kyverna Therapeutics (Nasdaq: KYTX) will participate in the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, at 11:20 a.m., featuring a fireside chat and investor meetings.
Why It Matters
Kyverna Therapeutics' participation in key conferences signals active engagement with investors and may provide insights into its pipeline, influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A late-breaking oral presentation will showcase primary analysis results from the KYSA-8 registrational trial for stiff person syndrome (SPS).
Why It Matters
The presentation of primary analysis from the KYSA-8 trial could influence investor sentiment on the drug's potential market approval and impact the company's stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kyverna Therapeutics' KYV-101 shows strong efficacy in autoimmune trials, targeting a BLA filing in 1H 2026. With $279M cash into 2028, the company is well-funded and backed by top investors.
Why It Matters
Kyverna Therapeutics' CAR-T therapy shows strong trial results, positioning it for regulatory approval. A solid cash runway and institutional support reduce dilution risk, making it an attractive investment.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About KYTX Stock
What is Kyverna Therapeutics, Inc.'s (KYTX) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Kyverna Therapeutics, Inc. (KYTX) has a median price target of $32.00. The highest price target is $33.00 and the lowest is $20.00.
Is KYTX stock a good investment in 2026?
According to current analyst ratings, KYTX has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.93. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KYTX stock?
Wall Street analysts predict KYTX stock could reach $32.00 in the next 12 months. This represents a 222.3% increase from the current price of $9.93. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kyverna Therapeutics, Inc.'s business model?
Kyverna Therapeutics generates revenue through the development and commercialization of advanced cell therapies, specifically engineered T cell therapies aimed at treating autoimmune disorders. The company focuses on R&D to create solutions that can provide long-lasting relief and improve patients' quality of life.
What is the highest forecasted price for KYTX Kyverna Therapeutics, Inc.?
The highest price target for KYTX is $33.00 from Derek Archila at Wells Fargo, which represents a 232.3% increase from the current price of $9.93.
What is the lowest forecasted price for KYTX Kyverna Therapeutics, Inc.?
The lowest price target for KYTX is $20.00 from Mitchell S. Kapoor at HC Wainwright & Co., which represents a 101.4% increase from the current price of $9.93.
What is the overall KYTX consensus from analysts for Kyverna Therapeutics, Inc.?
The overall analyst consensus for KYTX is bullish. Out of 7 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $32.00.
How accurate are KYTX stock price projections?
Stock price projections, including those for Kyverna Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 5:47 PM UTC